Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
melphalan + prednisone + doxorubicin + vincristine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**melphalan + prednisone + doxorubicin + vincristine (VBAP)** is a combination chemotherapy regimen used primarily for induction therapy in multiple myeloma. It consists of the DNA alkylator **melphalan**, corticosteroid **prednisone**, anthracycline **doxorubicin** (which intercalates DNA and inhibits topoisomerase II), and vinca alkaloid **vincristine** (which disrupts microtubule formation). Developed through clinical trials in the 1980s-1990s by groups like the Southwest Oncology Group and Italian cooperative studies, VBAP has been evaluated in alternating regimens (e.g., VMCP/VBAP) against standard melphalan + prednisone, showing comparable response rates around 45-60% but no survival advantage.
- Other names
- VBAP
02
Targets
DNATOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)Microtubule
Beyond the preview
Go deeper on melphalan + prednisone + doxorubicin + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on melphalan + prednisone + doxorubicin + vincristine.